
Tag: Rituximab

Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
POLARIX: Novel regimen superior to R-CHOP in DLBCL

Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL
Vaccine booster improves immune response in patients treated with rituximab
Ultra-low dosing of rituximab in RA is a viable treatment option
Sequential rituximab after belimumab does not improve disease control in SLE


Rituximab most effective initial MS therapy in Swedish real-world study
MS patients at risk of hampered immune response after vaccination

Anti-CD20 antibodies associated with worse COVID-19 outcomes
Acquired TTP: new treatments and updated guidelines
Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL
MATRix with ASCT: best long-term survival for primary CNS lymphoma
Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
Rituximab or JAK inhibitors increase the risk of severe COVID-19

Updates on COVID-19 vaccines in patients with rheumatic disease
JAK inhibitors and bDMARDs show comparable effectiveness

Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?
Rheumatoid arthritis and interstitial lung disease: a deadly combination
